23andMe has entered a strategic partnership with Nightingale Health to provide Nightingale Health's blood metabolomics panel to selected 23andMe members. The partnership aims to make blood testing more efficient, accessible, and informative.
The collaboration involves piloting Nightingale Health's clinically verified blood metabolomics panel with a cohort of 23andMe members to measure various biomarkers in a single blood sample. The data from this blood testing can enhance the accuracy of disease risk predictions and provide helpful insights into lifestyle interventions beneficial for a customer's health.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.